Published in final edited form as:

Gastroenterol Clin North Am. 2008 March ; 37(1): 73–vi. doi:10.1016/j.gtc.2007.12.008.

Prevention of Colorectal Cancer: Diet, Chemoprevention and Lifestyle

James R. Marshall, PhD

Dr. James Marshall, Professor of Oncology, Roswell Park Cancer Institute, Elm & Carlton, Buffalo, N.Y. 14263, James.Marshall@RoswellPark.org

Introduction

The goal of this chapter is to describe primary prevention of colon cancer, i.e. interventions that do not involve the removal of diseased tissue or chemotherapy for known colon cancer. Although screening with ablation of adenomas has a significant impact on colon cancer¹, the logistics of screening is very complicated²⁻⁴. These issues are addressed in accompanying chapters. This chapter focuses on preventing the initiation and promotion of neoplastic growth, particularly with dietary measures. A goal of dietary epidemiology is to identify chemopreventive agents and strategies. The effects of diet are analyzed by observational approaches and experimental dietary, nutritional, or chemopreventive interventions.

The adenomatous polyp or adenoma is an important surrogate endpoint for colon cancer⁵⁻⁷. The adenoma often remains indolent for years, so it can be analyzed in terms of prevalence. The adenoma is common among older individuals, especially those more than 50 years old. As many as 30% to 50% of individuals over the age of 50 harbor one or more adenomatous polyps⁸.

The adenoma is usually asymptomatic and is generally discovered only during routine screening. The adenoma is the key premalignant lesion that leads to colon cancer^{5, 6}. Many, if not most, adenomas never progress to colon cancer, but most colon cancers emerge from adenomas (adenoma-to-carcinoma sequence). As the adenoma is more common than colon cancer and new adenomas develop in individuals who have had previous adenomas that were ablated, studies of interventions designed to prevent colon cancer usually analyze the adenoma as a surrogate marker. This strategy is based on preventing colon cancer by preventing adenomas. The weakness of this strategy is that the formation of adenomas does not guarantee that an individual is at increased colon cancer risk, but this weakness has not deterred investigators from studying the adenoma as a surrogate marker for human colon cancer.

The proportion of colon cancer attributable to genetic syndromes--familial adenomatous polyposis and hereditary nonpolyposis colon cancer—appears to be small, so that screening for these two syndromes is unlikely to substantially reduce the incidence of colon cancer. Although these syndromes are powerful predictors of colon cancer, they are relatively uncommon and contribute a relatively small proportion to the total colon cancer burden.

Observational epidemiology

The epidemiologic literature is replete with studies that claim that various dietary factors affect colon cancer risk, either by reducing or increasing the risk. This epidemiologic literature must be read critically. The possibility of small-sample variation, as well as of outright bias in studies is great. In addition, the study design--the means by which data was collected--may affect the nature and quality of the findings. A historically important study design has been the ecologic method. In this design, political entities, rather than individuals, is the unit of analysis. The cancer risk or mortality of several countries is analyzed, together with the typical exposure level within each country; the analytic task is to then correlate each country's cancer risk or mortality with the country's mean exposure level⁹.

A better and more common study design is the case-control method, in which a sample of cases diagnosed with the disease are enrolled along with a sample of controls. The prior exposure of cases versus controls is then analyzed. If a given exposure increases the risk of disease, those with the disease should have experienced greater exposure than the controls¹⁰. Case-control studies are very efficient and are relatively inexpensive to perform.

The cohort method is regarded as the scientifically most valid observational epidemiologic study design. The exposure of each member of an assembled cohort is assessed using a standardized measure, such as a questionnaire¹¹. Occasionally, the exposure data is obtained from a biologic sample, such as blood. After exposure data are procured, the cohort is followed over time, and the analysis considers whether those with greater exposure to a putative risk factor experience a greater incidence of the disease. Since the risk of a particular cancer within a brief period is small, cohort studies must be large, and the cohorts must be followed for several years.

Clinical trials

Several dietary hypotheses have emerged from observational studies, such as case-control and prospective cohort studies; in almost every case, though, attempts to experimentally validate these findings have failed.

Because of the ambiguities of observational studies, researchers have increasingly instituted prevention trials to identify means of preventing colon cancer. A key element in these trials is random assignment to one intervention, or another, or nonintervention, so that intervention is independent of any other characteristic of trial participants: experimental and control subjects will tend to be alike in baseline height, weight, smoking, social class, physical activity, and other characteristics.

Prevention trials directly test an intervention; they evaluate whether dietary, nutritional, or chemopreventive intervention alters the risk of an individual. Observational studies merely focus on the association between dietary practice or nutrient exposure and risk of disease, i.e. whether variance in practice or exposure predicts elevated or diminished disease risk. Analyses based on cross-sectional variance in practice assume that changing an individual's exposure can alter individual risk. If, for example, greater red meat consumption predicts elevated risk of colon cancer, individuals with above-average intake should decrease their colon cancer risk by decreasing their red meat consumption. This assumption, although reasonable, is largely unproven. Furthermore, the length of time required for the risk to change is generally unknown and would be daunting to accurately specify empirically.

A complication of prevention trials, involving altered behavior or environmental exposure, is that they often can not be administered under conditions of blinding: subjects know whether they are assigned to an intervention. In addition, behavioral change is difficult to implement

and to maintain long term. The Polyp Prevention Trial required subjects to adopt and maintain a dietary change for four years¹². Recidivism among experimental subjects diminishes the differences between them and control subjects. Behavioral changes rarely happen in isolation. The goal of experiments is often to identify the impact of a single change, such as smoking cessation, increased physical activity, or a dietary change.

Diet and colon cancer prevention

The analysis of dietary data is highly complex. Hundreds of food items are commonly consumed in Western societies, and the numbers of dietary elements—macronutrients, micronutrients, and minerals—extracted from foods, is in the thousands. Analysis of these items is therefore complex.

The Western Diet: Fat and Fiber

Dr. Denis Burkitt observed in 1971¹³ that the diets and stools of the native peoples of South Africa were much different from those of Westerners and they had a very different incidence of colon cancer. He proposed that the high fiber content of these peoples could protect against colon cancer. Formal analyses of ecologic data revealed strong associations of dietary fat, and strong negative associations of dietary fiber, with colon cancer risk⁹. An early case-control study indicated that a history of elevated dietary fat intake increased risk¹⁴. While a study based on a large, hospital-based sample of cases and controls, provided no evidence that dietary fat was associated with increased risk¹⁵, an equally large and well executed case-control analysis revealed a strong association of dietary fat with colon cancer risk¹⁶. One of the best studies of diet and colon cancer, the prospective Nurses Health Study, indicated that dietary fiber does not affect the risk of subsequent colon cancer¹⁷. Although some fruits and vegetables, which contribute fiber to the diet, may be protective, dietary fiber alone appears to have no impact on colon cancer risk¹⁷.

Alberts and colleagues¹⁸ directly tested Burkitt's provocative hypothesis in a double-blind, placebo-controlled clinical prevention trial. They randomized 1,429 adenoma patients to a high-fiber versus a low-fiber cereal supplement. Compliance with the study protocol was high. Recurrence rates among experimental and placebo subjects were virtually identical. Although experimental subjects were slightly less likely than placebo patients to take their supplement, adjustment for imperfect compliance made no difference; assignment to the high-fiber supplement did not affect the risk of recurrence.

Although interest in the role of dietary fat and fiber in the genesis of colon cancer has persisted, the accumulated evidence has been unconvincing. The strongest of the cohort studies indicates that dietary fat, per se, does not increase the risk of colon cancer^{17, 19}, but that some foods that contribute fat to the diet, especially red meat, may increase the risk¹⁹.

Fruit and Vegetable Consumption

Graham's analysis, indicated that intake of cruciferous vegetables, such as broccoli, cabbage and cauliflower, decreased the cancer risk¹⁵. A subsequent report by Graham et al, with a more detailed dietary assessment, showed cases consumed fewer fruits and vegetables than controls. Nonetheless, no association between cruciferous vegetable consumption and risk was observed²⁰. A recently published compendium of case-control studies indicated that cruciferous vegetable consumption was associated with a modest (15%) decrease in colon cancer risk²¹. Cohort and prospective studies provide stronger evidence that dietary cruciferous vegetable intake decreases the colon cancer risk by approximately 25%²¹. The evidence regarding colon cancer protection is stronger for cruciferous than for other vegetables. A meta-analysis of case-control studies suggests that fruit and vegetable consumption in

general is associated with a slight decrease in the risk of colon cancer²². For example, fruit consumption is associated with a 13% decrease in colon cancer risk, and vegetable consumption is associated with a 40% decrease. The strength of the association is, however, variable. Furthermore, the cohort evidence is less compelling^{22, 23}.

The Polyp Prevention Trial constitutes an important attempt to analyze the effect of dietary intervention among patients with adenomatous polyps in preventing polyp recurrence^{12,24}. The intervention achieved statistically significant changes in dietary practice, while the diets of the control subjects did not change, as confirmed by analysis of blood tests¹². Nevertheless, dietary intervention had no impact on the recurrence of adenomatous polyps compared to control subjects, including the total number of adenomas, the number of adenomas by site, or the number of high-risk or advanced adenomas¹². A 17-year follow-up revealed no impact of this 4-year long dietary intervention on the total adenoma rate or colon cancer risk²⁵. The Women's Health Initiative dietary intervention trial reported similarly disappointing results²⁶. In this randomized trial of dietary intervention of some 48,000 women followed for an average of more than 8 years, the subsequent risk of colon cancer for experimental and control patients was virtually identical²⁶.

Antioxidants

There is excellent evidence that oxidative stress contributes to the risks of chronic diseases, including cancers²⁷. Whether this mechanism is important in colorectal cancer is not completely clear. It was hoped that antioxidant dietary constituents, including vitamins C and E, and carotenoids, might protect against oxidative stress and thereby decrease cancer risk²⁸. However, an important, interventional trial reported no evidence of reduction of the risk of adenoma recurrence from administration of beta carotene and vitamins C and E²⁹. Compliance with study medications, as reflected by blood nutrient levels, was extremely high.

Non-steroidal anti-inflammatory drugs

Interest in the use of non-steroidal anti-inflammatory drugs stemmed from the observation that individuals who chronically used large amounts of aspirin had decreased mortality from colorectal cancer³⁰. This finding was supported by other studies³¹⁻³³. Subsequent reports based on clinical trials have generally supported this observation. In a study of 635 patients randomized to receive either 325 mg/day of aspirin or placebo after colorectal cancer surgery, the relative risk of adenoma among those randomized to aspirin was approximately 0.65³². In a study of 1,121 patients with a history of adenoma randomized to receive placebo, 81 mg aspirin, or 325 mg aspirin, the relative risk of adenoma recurrence was 0.81 in the 81 mg group, and 0.96 in the 325 mg group³⁴. Why 81 mg/day of aspirin significantly decreased adenoma recurrence, while 325 mg/day did not, is puzzling³⁴. Although these results are encouraging, the use of aspirin as a chemopreventive agent entails risks: as an anticoagulant, it can lead to excessive bleeding; and as an inhibitor of cyclooxygenase 1 activity it can lead to intestinal bleeding. Therefore, other anti-inflammatory drugs were studied^{35, 36}. These agents unfortunately have cardiovascular toxicity that renders them unsuitable for chemoprevention³⁷.

Selenium

Clark's trial of selenium supplementation among nonmelanoma skin cancer patients was partly motivated by ecologic data indicating that regions of the United States where ambient soil selenium levels were low had elevated risks of several cancers³⁸. Clark's intervention resulted in a nearly 50% decrease in colon cancer risk among patients receiving selenium supplementation; unfortunately, the statistical significance of the decrease in risk was marginal due to the small number of patients in the study who developed colon cancer. Extended follow-

up analysis of Clark's data reveals that assignment to selenium supplementation was also associated with a decreased risk of developing adenomatous polyps³⁹. Numerous animal studies have shown that selenium has antineoplastic properties⁴⁰. In addition observational studies have revealed decreases in colon cancer risk among those with elevated selenium intake⁴¹.

Calcium

Observational epidemiological evidence suggests that calcium protects against colon cancer⁴². Baron's randomized, controlled trial provided even stronger evidence³⁴. The relative risk of adenoma recurrence among those assigned to receive calcium was 0.85, and the ratio of adenomatous polyps among experimental versus control patients was 0.76. Both effects were statistically significant. However, the decline in adenoma risk associated with calcium supplementation was only 15%. Whether this small decrease would justify widespread calcium supplementation is debatable. No subgroup of subjects was affected enough to alter the standard colon cancer screening schedule.

Folate

Evidence derived from *in vitro* and *in vivo* models strongly suggests that folate should protect against colon cancer^{43, 44}. Baron and colleagues in a cohort study conducted within a randomized clinical trial, found that folate intake at baseline was associated with a statistically significant reduced risk of adenoma recurrence⁴⁵. Adjustment for likely confounders, for total energy and for dietary fiber intake, however, obliterated this effect. On the other hand, alcohol intake, which diminishes folate levels, was associated with a greater than twofold increase in adenoma recurrence⁴⁶. The reduction in risk with folate may be as high as 40%. In a study of male health professionals, a high dietary folate intake was weakly associated with a decreased risk of colon cancer⁴⁷. A more recent study found that folate intake for more than 15 years was associated with a sizeable, statistically significant, decrease in colon cancer. In these studies, alcohol intake was again associated with increased colon cancer risk, and this association was stronger than that for folate.

Lifestyle

Several aspects of lifestyle, including body mass, physical activity, and smoking have been analyzed as possible colon cancer risk factors.

Body mass

Elevated body mass, or obesity, partly represents energy balance, or the juxtaposition of energy intake and expenditure. On an ecologic level, Western industrialized countries have increased obesity and an increased colon cancer risk. The epidemiologic literature is relatively consistent: case-control and prospective studies show obesity is associated with increased risk⁴². The mechanisms of the association are not well understood; hormonal factors for women, or insulin metabolism have been proposed⁴². Alteration of inflammatory processes is possible; Martinez reported a strongly positive association between body mass index and prostaglandin E₂, a marker of inflammation and inflammatory responses⁴⁸. There have been no experimental evaluations of this association, or whether weight-loss can decrease colon cancer risk.

Physical activity

Physical activity, a component of energy expenditure and energy balance, may, by itself, be associated with decreased colon cancer risk⁴². Much of the recent literature has emphasized recreational physical activity^{48,49}. The mechanisms of this effect are poorly understood.

Martinez et al.⁴⁸ showed a statistically significant, positive association between rectal mucosal prostaglandin E2 levels and body mass, and a negative association between rectal mucosal prostaglandin E2 levels and physical activity.

Smoking

The pathogenicity of tobacco smoking for pulmonary and urologic cancers and for heart and lung disease is well established and understood. Early studies of colon cancer did not show smoking to be associated with increased risk⁵⁰. It now appears that the effects of smoking on colon cancer require decades of exposure. Only individuals with long periods of smoking have increased risk of adenomatous polyps^{41, 42}; this risk may be increased as much as three-fold. The increased risk of colon cancer may take even longer to manifest; competing causes of death may diminish the impact of smoking.

The association between smoking and colon cancer is not as strong as those between smoking and pulmonary cancers. Nonetheless, the effect is significant, and attempts to prevent colon cancer should include control of smoking. The risk of colon cancer among long-term smokers is approximately doubled^{51, 52}. Thus smoking increases the risk of colon cancer more than any known chemopreventive agent decreases the risk. The mechanisms of this association are poorly understood; carcinogenic smoking byproducts are carried in the blood and could infuse the colon, while smoke entering through the mouth could be ingested with food and transported to the colonic lumen.

Challenges for future progress in colon cancer prevention

Major questions concerning the etiology of colon cancer remain to be resolved. Two major exposure routes are possible: the fecal stream within the colonic lumen and transmission via the blood circulation to the colon. For example, the concentration of deoxycholate and related compounds in stool has received much attention⁵³. Blood is the major, if not only, means by which compounds initiating and promoting neoplastic growth could be transmitted to many other tissues—breast, prostate, liver, brain. Factors transmitted by the circulatory system could be related to the etiology, and hence to the prevention, of colon cancer. Clearly, further understanding of the etiology of colon cancer is needed.

Several options are available to prevent colon cancer. The most important is screening^{1, 2, 4}. However, the costs of screening are considerable⁴, and there are at present not enough trained medical personnel to screen the entire eligible population of the United States.

Diet may play a moderate role in colon cancer risk, but the effect of diet may be underestimated due to imprecise dietary measurements due to the complexity of the diet^{54,55}. Short-term trials that alter intermediate biomarkers, that are more sensitive than the adenoma to interventions, may be necessary. The same logic needs to be applied to chemoprevention. NSAIDs, calcium and selenium have some individual effects that could be potentiated if added together. The current evidence is that the combined effect of all three agents is modest, compared to the effects of screening, or even that of smoking cessation.

References

1. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. *N Engl J Med* 2000;343(22):1603–1607. [PubMed: 11096167]
2. Byers T, Levin B, Rothenberger D, Dodd GD, Smith RA. For the American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. American cancer society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: Update 1997. *CA: A Cancer Journal for Clinicians* 1997;47(3):154–160. [PubMed: 9152173]

3. Lance P, Grossman S, Marshall JR. Screening for colorectal cancer. *Seminars in Gastrointestinal Diseases* 1992;3:22–33.
4. Marshall JR, Fay D, Lance P. Potential costs of flexible sigmoidoscopy-based colorectal cancer screening. *Gastroenterology* 1996;111(6):1411–1417. [PubMed: 8942718]
5. Schatzkin A, Freedman LS, Schiffman MH, Dawsey SM. Validation of intermediate end points in cancer research. *J Natl Cancer Inst* 1990;82(22):1746–1752. [PubMed: 2231769]
6. Schatzkin A, Freedman LS, Dorgan J, McShane LM, Schiffman MH, Dawsey SM. Surrogate end points in cancer research: A critique. *Cancer Epidemiology Biomarkers & Prevention* 1996 December; 5:947–953.
7. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988;319(9):525–532. [PubMed: 2841597]
8. Schatzkin A, Freedman LS, Dawsey S, Lanza E. Interpreting precursor studies: What polyp trials tell us about large bowel cancer. *J Natl Cancer Inst* 1994;86:1053–1057. [PubMed: 7802771]
9. Winder EL, Reddy BS. Metabolic epidemiology of colorectal cancer. *Cancer* 1974;34:801–806. [PubMed: 4853174]
10. Cornfield, J. A Statistical Problem Arising From Retrospective Studies. In: Neyman, Je, editor. *Priceedings of the Third Berkeley Symposium*. Berkeley: University of California Press; 1956. p. 135-148.
11. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Hennekens CH, Speizer FE. Dietary fat and the risk of breast cancer. *N Engl J Med* 1987;316(1):22–28. [PubMed: 3785347]
12. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas: The polyp prevention trial study group. *N Engl J Med* 2000;342(16):1149–1155. [PubMed: 10770979]
13. Burkitt DP. Epidemiology of cancer of the colon and rectum. *Cancer* 1971;28:3–13. [PubMed: 5165022]
14. Wynder EL. Amount and type of Fat/Fiber in nutritional carcinogenesis. *Prev Med* 1987;16:451–459. [PubMed: 2819846]
15. Graham S, Dagal H, Swanson M, Mittelman A, Wilkinson G. Diet in the epidemiology of cancer of the colon and rectum 79. *J Natl Cancer Inst* 1978;61:709–714. [PubMed: 278848]
16. Howe GR, Miller AB, Jain M, Cook G. Dietary factors in relation to the etiology of colorectal cancer. *Cancer Detection & Prevention* 1982;5:331–334. [PubMed: 7151066]
17. Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. *N Engl J Med* 1999;340(3):169–176. [PubMed: 9895396]
18. Alberts DS, Martinez ME, Roe DJ, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. *N Engl J Med* 2000;342(16):1156–1162. [PubMed: 10770980]
19. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Speizer FE. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. *N Engl J Med* 1990;323(24):1664–1672. [PubMed: 2172820]
20. Graham S, Marshall J, Haughey B, et al. Dietary epidemiology of cancer of the colon in western new york. *Am J Epidemiol* 1988;128(3):490–503. [PubMed: 2843038]
21. International Agency for Research on Cancer. *Cruciferous Vegetables, Isothiocyanates and Indoles*. Lyon, France: IARC Press; 2004.
22. International Agency for Research on Cancer. *Fruit and Vegetables*. Lyon, France: IARC Press; 2003.
23. Michels KB, Giovannucci E, Joshipura KJ, et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. *J Natl Cancer Inst* 2000;92(21):1740–1752. [PubMed: 11058617]
24. Schatzkin A, Lanza E, Freedman LS, et al. The polyp prevention trial I: Rationale, design, recruitment, and baseline participant characteristics. *Cancer Epidemiology Biomarkers & Prevention* 1996;5:375–383.
25. Schatzkin A, Mouw T, Park Y, et al. Dietary fiber and whole-grain consumption in relation to colorectal cancer in the NIH-AARP diet and health study. *Am J Clin Nutr* 2007;85(5):1353–1360. [PubMed: 17490973]

26. Beresford SAA, Johnson KC, Ritenbaugh C, et al. Low-fat dietary pattern and risk of colorectal cancer the women's health initiative randomized controlled dietary modification trial. *J Am Med Assoc* 2006;295(6):643–654.
27. Institute of Medicine (IOM). Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC: National Academy Press; 2000.
28. Block G, Subar AF. Estimates of nutrient intake from a food frequency questionnaire: The 1987 national health interview survey. *J Am Diet Assoc* 1992;92(8):969–977. [PubMed: 1640041]
29. Greenberg ER, Baron JA, Tosteson TD, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. *N Engl J Med* 1994;331(3):141–147. [PubMed: 8008027]
30. Thun MJ, Calle EE, Namboodiri MM, et al. Risk factors for fatal colon cancer in a large prospective study. *J Natl Cancer Inst* 1992;84(19):1491–1500. [PubMed: 1433333]
31. Neugut AI, Jacobson JS, DeVivo I. Epidemiology of colorectal adenomatous polyps. *CEBP* 1993;2:159–176.
32. Peipins LA, Sandler RS. Epidemiology of colorectal adenomas. *Epidemiol Rev* 1994;16:273–297. [PubMed: 7713180]
33. Arber N. Do NSAIDs prevent colorectal cancer? *Can J Gastroenterol* 2000;14:299–307. [PubMed: 10799083]
34. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. *N Engl J Med* 2003;348(10):891–899. [PubMed: 12621133]
35. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *NEJM* 2000;342:1946–1952. [PubMed: 10874062]
36. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. *Nat Rev Cancer* 2001;1:11–21. [PubMed: 11900248]
37. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. *The New England Journal of Medicine* 2006;355(9):873–884. [PubMed: 16943400]
38. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin A randomized controlled trial. *J Am Med Assoc* 1996;276(24):1957–1963.
39. Reid ME, Combs GF, Duffield-Lillico AJ, et al. The Association between Baseline Selenium, Alpha and Gamma Tocopherol, and the Effect of Selenium Supplementation on Cancer Incidence. 2005
40. Combs, GF.; Combs, SB. *The Role of Selenium in Nutrition*. New York: Academic Press; 1986.
41. Martinez, ME.; Marshall, JR. Environmental and life style issues in colorectal cancer. In: Levin, B.; Kelsen, DP.; Daly, JM.; Kern, SE.; Tepper, JE., editors. *Gastrointestinal Oncology: Principles and Practices*. Philadelphia, PA: Lippincott Williams and Wilkins; 2002. p. 665-683.
42. Giovannucci, E.; Wu, K. Cancers of the colon and rectum. In: Schottenfeld, D.; Fraumeni, JF., editors. *Cancer Epidemiology and Prevention*. Vol. 3. New York: Oxford; 2006. p. 809-829.
43. Kim YI, Christman JK, Fleet JC, et al. Moderate Folate Deficiency does Not Cause Global Hypomethylation of Hepatic and Colonic DNA of C-Myc-Specific Hypomethylation of Colonic DNA in Rats. *Am J Clin Nutr* 1995;61(5):1083–1090. [PubMed: 7733033]
44. Choi SW, Mason JB. Folate and carcinogenesis: An integrated scheme. *J Nutr* 2000;130:129–132. [PubMed: 10720158]
45. Baron JA, Sandler RS, Haile RW, Mandel JS, Mott LA, Greenberg ER. Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas 371. *J Natl Cancer Inst* 1998;90(1):57–62. [PubMed: 9428784]
46. Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma 75. *J Natl Cancer Inst* 1993;85:875–884. [PubMed: 8492316]
47. Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Willett WC. Alcohol, low-methionine--low-folate diets, and risk of colon cancer in men. *J Natl Cancer Inst* 1995;87(4):265–273. [PubMed: 7707417]
48. Martinez EM, Heddens D, Earnest DL, et al. Physical activity, body mass index, and prostaglandin E2 levels in rectal mucosa. *J Natl Cancer Inst* 1999;91(11):950–953. [PubMed: 10359547]
49. Martinez EM, Giovannucci E, Spiegelman D, et al. Leisure-time physical activity, body size, and colon cancer in women. *J Natl Cancer Inst* 1997;89(13):948–955. [PubMed: 9214674]

50. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male british doctors. *Br Med J* 1976 December 25;2:1525–1536. [PubMed: 1009386]
51. Giovannucci E, Colditz GA, Stampfer MJ, et al. A Prospective Study of Cigarette Smoking and Risk of Colorectal Adenoma and Colorectal Cancer in U.S. Women. *J Natl Cancer Inst* 1994;86(3):192–199. [PubMed: 8283491]See Comments
52. Giovannucci E, Rimm EB, Stampfer MJ, et al. A Prospective Study of Cigarette Smoking and Risk of Colorectal Adenoma and Colorectal Cancer in U.S. Men. *J Natl Cancer Inst* 1994;86(3):183–191. [PubMed: 8283490]See Comments
53. Marshall, JR.; Alberts, DS. Future strategies for the medical prevention of colorectal cancer. In: Schmiegel, W.; Scholmerich, J., editors. *Colorectal Cancer Molecular Mechanisms, Premalignant State and its Prevention*. Hingham MA: Kluwer Academic Publishers BV; 1999.
54. Marshall JR, Hastrup JL. Mismeasurement and the resonance of strong confounders: Uncorrelated errors. *Am J Epidemiol* 1996;143(10):1069–1078. [PubMed: 8629614]
55. Marshall J, Hastrup JL, Ross JS. Mismeasurement and the resonance of strong confounders: Correlated errors. *Am J Epidemiol* 1999;150(1):88–96. [PubMed: 10400558]